Generation of Broad Protection against Influenza with Di-Tyrosine-Cross-Linked M2e Nanoclusters

ACS Infect Dis. 2024 May 10;10(5):1552-1560. doi: 10.1021/acsinfecdis.3c00429. Epub 2024 Apr 16.

Abstract

Tyrosine cross-linking has recently been used to produce nanoclusters (NCs) from peptides to enhance their immunogenicity. In this study, NCs were generated using the ectodomain of the ion channel Matrix 2 (M2e) protein, a conserved influenza surface antigen. The NCs were administered via intranasal (IN) or intramuscular (IM) routes in a mouse model in a prime-boost regimen in the presence of the adjuvant CpG. After boost, a significant increase in anti-M2e IgG and its subtypes was observed in the serum and lungs of mice vaccinated through the IM and IN routes; however, significant enhancement in anti-M2e IgA in lungs was observed only in the IN group. Analysis of cytokine concentrations in stimulated splenocyte cultures indicated a Th1/Th17-biased response. Mice were challenged with a lethal dose of A/California/07/2009 (H1N1pdm), A/Puerto Rico/08/1934 (H1N1), or A/Hong Kong/08/1968 (H3N2) strains. Mice that received M2e NCs + CpG were significantly protected against these strains and showed decreased lung viral titers compared with the naive mice and M2e NC-alone groups. The IN-vaccinated group showed superior protection against the H3N2 strain as compared to the IM group. This research extends our earlier efforts involving the tyrosine-based cross-linking method and highlights the potential of this technology in enhancing the immunogenicity of short peptide immunogens.

Keywords: M2e; cross-linking; influenza; nanocluster; tyrosine; vaccine.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adjuvants, Immunologic / administration & dosage
  • Adjuvants, Immunologic / pharmacology
  • Administration, Intranasal
  • Animals
  • Antibodies, Viral* / blood
  • Antibodies, Viral* / immunology
  • Cross Protection
  • Cytokines
  • Female
  • Influenza A Virus, H1N1 Subtype* / immunology
  • Influenza A Virus, H3N2 Subtype / immunology
  • Influenza Vaccines* / administration & dosage
  • Influenza Vaccines* / immunology
  • Injections, Intramuscular
  • Lung / immunology
  • Lung / virology
  • Mice
  • Mice, Inbred BALB C
  • Orthomyxoviridae Infections* / immunology
  • Orthomyxoviridae Infections* / prevention & control
  • Tyrosine* / chemistry
  • Tyrosine* / pharmacology
  • Viral Matrix Proteins / genetics
  • Viral Matrix Proteins / immunology
  • Viroporin Proteins

Substances

  • Influenza Vaccines
  • Tyrosine
  • Antibodies, Viral
  • Viral Matrix Proteins
  • M2 protein, Influenza A virus
  • Adjuvants, Immunologic
  • Cytokines
  • Viroporin Proteins